Sharechat Logo

RESEND: ResMed amends US trade complaint against F&P Healthcare, other actions still proceeding

Wednesday 17th May 2017

Text too small?

(Fixes CEO name in 3rd paragraph) ResMed has withdrawn its complaint against Fisher & Paykel Healthcare in the US International Trade Commission but plans to replace it with a new action and is still pursuing its patent dispute with the New Zealand maker of breathing masks in several other jurisdictions. 

The Auckland-based company has been told ResMed filed an unopposed motion to terminate the investigation after withdrawing its complaint in the US trade agency while indicating it plans to file a new complaint, F&P Healthcare said in a statement. The withdrawal doesn't affect other patent litigation between the companies, F&P Healthcare said. 

"We are pleased with today’s developments. As we said when these proceedings commenced in August last year we are confident in our intellectual property position," F&P Healthcare chief executive Lewis Gradon said. "Should ResMed request that the ITC conduct another investigation, we will vigorously contest this and we remain confident in regards to future proceedings." 

The action is one of several where the breathing mask makers are at odds over their intellectual property in Germany, New Zealand, the UK and the US district court, and could block F&P Healthcare imports to the US if excluded by the commission. 

F&P Healthcare shares rose 2.4 percent to $10.25 and have gained 17 percent so far this year. Investors have been treating the stock as a proxy for exposure to the US, where the company derives half of its revenue and where the Trump administration is taking a hardline stance on America's trade relationship with Mexico. F&P Healthcare has major manufacturing facilities in Mexico. 

 

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

PaySauce Quarterly Market Update - Dec 2024
CHI - FY24 Results Date and Audio Conference Details
AIA - December 2024 Monthly traffic update
January 15th Morning Report
PF - Details of Interim Results Webcast
Scott Secures NZ$18 million in Global Contracts for Protein
January 14th Morning Report
AFT - NEW YEAR LETTER TO INVESTORS
TruScreen Invited to Present WHO AI Collaboration Meeting
January 13th Morning Report